Form 4: Mineralys Therapeutics Chief Medical Officer Executes Stock Option Under 10b5-1 Plan

David Malcom Rodman, Chief Medical Officer of Mineralys Therapeutics, exercised a stock option for 6,349 shares at $1.08 per share under a pre-arranged 10b5-1 trading plan.

Summary

• David Malcom Rodman, the Chief Medical Officer of Mineralys Therapeutics, Inc. (MLYS), executed a transaction involving common stock and stock options on May 12, 2025.
• Rodman acquired 6,349 shares of common stock at a price of $1.08 through the exercise of a stock option.
• This transaction was conducted under a Rule 10b5-1 trading plan adopted on October 25, 2024.
• Following the transaction, Rodman directly owns 118,035 shares of common stock and 101,577 stock options.
• The stock option vests in installments, beginning with 25% on July 12, 2022, and the remainder in 36 equal monthly installments.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing detailing an insider transaction. It doesn't inherently convey positive or negative sentiment.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track ownership changes and potential alignment of interests.

Key Dates

Keywords

Mineralys Therapeutics, MLYS, David Malcom Rodman, Chief Medical Officer, Stock Option, Form 4, 10b5-1 Trading Plan, Beneficial Ownership, Securities Exchange Act